Gastroenterology
Volume 135, Issue 5 , Pages 1442-1447, November 2008

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

  • William J. Sandborn

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: William J. Sandborn, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. fax: (507) 266-0335

Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota

published online 09 October 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The author discloses the following: Dr Sandborn is supported by Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma. Dr Sandborn is a consultant for Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Salix Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma, and Elan.

PII: S0016-5085(08)01784-8

doi:10.1053/j.gastro.2008.09.053

Gastroenterology
Volume 135, Issue 5 , Pages 1442-1447, November 2008

Article Tools

* Image Usage & Resolution